domvanalimab
domvanalimab: developed by 2 companies · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (2)
| Company | Phase |
|---|---|
| GILEAD SCIENCES, INC. (GILD) | Phase 2 |
| Arcus Biosciences, Inc. (RCUS) | Phase 1 |
Clinical Trials (1)
A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations
Frequently asked questions
Who is developing domvanalimab?
domvanalimab is being developed by GILEAD SCIENCES, INC., Arcus Biosciences, Inc..
How many clinical trials involve domvanalimab?
BioSniper tracks 1 clinical trial involving domvanalimab.
Get deeper analysis on domvanalimab
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis